ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mansour, K. A.
Right arrow Articles by Downey, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mansour, K. A.
Right arrow Articles by Downey, R. S.

The Annals of Thoracic Surgery, Vol 48, 201-204, Copyright © 1989 by The Society of Thoracic Surgeons


ARTICLES

Esophageal carcinoma: surgery without preoperative adjuvant chemotherapy

KA Mansour and RS Downey
Division of Thoracic and Cardiovascular Surgery, Joseph B. Whitehead Department of Surgery, Emory University School of Medicine, Atlanta, Georgia.

Our experience with 100 consecutive patients with esophageal carcinoma treated with surgical intervention as the primary method of therapy between 1967 and 1987 was reviewed. Preoperative chemotherapy was not administered by us. Follow-up was complete for all 100 patients. Twelve percent of tumors were in the proximal third of the esophagus, 21% were in the middle third, and 67% were in the distal third. Adenocarcinoma accounted for 44% of all tumors, squamous cell for 55%, and adenosquamous for 1%. Six patients were in stage I, 14 were in stage II, and 80 were in stage III; no patient was in stage IV. Surgical procedures included 85 esophagogastrectomies with primary anastomoses, 11 with colon interposition, and 4 with Roux-en-Y small-bowel interposition. Six patients had radical laryngopharyngo-esophagectomy with gastric or colopharyngeal anastomosis. Operative mortality was 3%. The mean survival of stage I patients was 182 months; stage II patients, 25 months; and stage III patients, 18 months. Our data show that surgical resection without preoperative adjuvant chemotherapy remains the cornerstone of therapy for patients with carcinoma of the esophagus.


This article has been cited by other articles:


Home page
ChestHome page
M. M. DeCamp Jr, S. J. Swanson, and M. T. Jaklitsch
Esophagectomy After Induction Chemoradiation*
Chest, December 1, 1999; 116(suppl_3): 466S - 469S.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. A. Mansour, V. H. Thourani, and W. A. Cooper
Esophageal Carcinoma: Surgery Without Preoperative Adjuvant Chemotherapy
Ann. Thorac. Surg., May 1, 1998; 65(5): 1492 - 1493.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
K. S. Naunheim, P. J. Petruska, T. S. Roy, J. M. Schlueter, H. Kim, and A. E. Baue
Multimodality Therapy for Adenocarcinoma of the Esophagus
Ann. Thorac. Surg., May 1, 1995; 59(5): 1085 - 1090.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1989 by The Society of Thoracic Surgeons.